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(IV) abatacept, adalimumab, etanercept or infliximab. Methods: This study was 
a retrospective analysis of administrative claims data from US managed care 
plans. Patients who initiated one of the following study biologic disease modifying 
antirheumatic drugs: IV abatacept, adalimumab, etanercept or infliximab were 
identified and date of initiation was defined as the index date. The identification 
period was 7/1/2004 through 3/31/2010. Patients were required to have continu-
ous eligibility in the 6 months pre-index (baseline) period and in the 12 months 
post-index (follow-up) period, were aged ≥ 18 years at index, and had ≥ 1 baseline 
medical claim with an ICD-9-CM diagnosis code for RA (714.0x, 714.2x). Outcomes 
evaluated in the 12 month follow-up period were total health care costs (medi-
cal + pharmacy) and switch rates. Generalized Estimating Equations were used 
to compare mean change from baseline in total health care costs between the 
treatment groups. Logistic regression analysis was used to compare the odds of 
switching between treatment groups after controlling for baseline characteris-
tics. Results: The study included 8505 first-line patients and 2181 second-line 
patients. In first-line patients change from baseline in monthly total health care 
costs were higher for etanercept (Cost Ratio (CR)= 1.26; p= 0.0112), adalimumab 
(CR= 1.30; p= 0.0065) and infliximab (CR= 1.10; p= 0.3355) compared to abatacept. In 
the first-line population, after controlling for baseline covariates, etanercept (Odds 
Ratio (OR)= 2.52, 95% confidence interval (CI):1.57, 4.05), adalimumab (OR= 2.33, 95% 
CI:1.44, 3.77) and infliximab (OR= 1.91, 95% CI:1.17, 3.13) had significantly higher 
odds of switching compared to abatacept. Results for the second-line population 
were consistent with results from the first line population. ConClusions: First 
or second-line abatacept patients had lowest mean change from baseline in total 
health care costs and lower rates of switching compared to adalimumab, etaner-
cept or infliximab patients.
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objeCtives: Osteoporotic vertebral compression fractures (OVCF) are among 
the most common fractures related to osteoporosis. They have been shown to be 
associated with excess mortality, and meaningful health care costs. Costs calcula-
tions have illustrated the significant financial burden to society and national social 
security systems. However, information on disease-related costs of OVCF is not 
available for Germany. Therefore, the aim of the present study was to estimate the 
direct disease-related costs of OVCF in patients with newly diagnosed fracture in 
the first year after index in Germany. Methods: Data was obtained from a claims 
dataset of a large German health insurance fund. Subjects ≥ 60 years with a new 
vertebral fracture between 2006 - 2010 were studied retrospectively compared to a 
matched paired OVCF-free patient group. All-cause and fracture-specific medical 
costs were calculated in the 1-year baseline and follow-up period. Generalized linear 
model (GLM) was estimated for total follow-up health care cost. Results: A total of 
2,277 pairs of matched OVCF and OVCF-free patients were included in the analysis. 
Baseline costs were higher in the OVCF group. Mean unadjusted all-cause health 
care cost difference in the 4 quarters following the index date between OVCF and 
OVCF-free patients was 8,200 € (p< 0.001). Of the difference, almost two-third was 
attributable to inpatient services and one-quarter to prescription drug costs. The 
GLM procedure revealed that OVCF-related costs in the first year after the index date 
add up to 6,490 € (p< 0.001; CI: 5,809 € - 6,731 € ). ConClusions: Despite limitations 
of this study, including sensitivity and specificity of claims-based diagnoses, and 
generalizability issues, our results are consistent with other research and dem-
onstrate that OVCF’s are associated with significant costs. In light of the high and 
increasing incidence and prevalence of these fractures, the results emphasize the 
importance of research in this field.
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objeCtives: The cost associated with fracture care exceeds $21 billion. Yet, not all 
fractures heal, leading to even further expenses. There is an economic and societal 
burden to surgical treatment. The purpose of this study is to compare the costs 
associated with surgical treatment versus non-invasive methods in managing non-
unions (fractures that have not healed). Methods: A retrospective cohort direct 
match study was performed using administrative claims (integrated medical and 
pharmacy data) from the IMS LifeLinkÔ Health Plan Claims Database. All patients 
with at least one claim for EXOGEN® Ultrasound Bone Healing System (non-invasive) 
or non-union surgery were identified between April 1, 2007 and March 31, 2010; data 
through March 31, 2011 were used. Results: 1,158 matched patients were selected 
(579 in ‘Exogen Only’ and 579 in ‘Surgery Only’ cohorts). Over the 12 month post-
index period, the Surgery Only cohort had higher mean total all-cause direct medical 
costs compared to the Exogen Only cohort ($25,850 vs. $18,813; p < 0.0001). Mean 
outpatient costs accounted for over 50% of the total all-cause overall costs in both 
cohorts and were significantly higher among the Surgery Only cohort compared to 
the Exogen Only cohort ($13,964 vs. $11,072; p < 0.0001). Total mean all-cause inpa-
tient costs were also significantly higher among the Surgery Only cohort compared 
to the Exogen Only cohort ($9,612 vs $5,298; p < 0.0001). Non-union fracture-related 
mean direct medical costs were over 126% higher in the Surgery Only group versus 
the Exogen Only group ($11,276 vs. $4,987; p < ,0.0001). ConClusions: Compared 
to surgery only, the use of Exogen only for the treatment of non-union fractures 
resulted in significant cost savings which could amount to $4 billion dollars annually 
in the US alone. Additional research is needed to further quantify true costs (both 
direct and indirect) as well as the cost-effectiveness of two treatment modalities 
while monitoring outcomes.
followed by a maintenance every 8 week + metotrexate 15 mg/week. This analysis 
was development for perspective of third payer. Only direct costs was used in the 
model: sourced drug acquisition and administration costs. Results: Inclusion 
of tocilizumab does not imply additional costs to the Colombian health system 
and may even save resources by 17 million dollars until 2017. In the probabil-
istic model, tocilizumab has a thrifty impact in most years. This model shows 
that yhe inclusion of Tocilizumab saves costs for the Colombian health sys-
tem (with increases of the inclusion, more saves) versus capitation payment 
unit (UPC). ConClusions: Inclusion of tocilizumab to mandatory health plan 
Colombia, would have an impact thrifty indicating that the health budget would 
not increase with inclusion.
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objeCtives: To estimate annual cost-per-treated patient and treatment patterns for 
etanercept, adalimumab, and infliximab in Medicaid beneficiaries with Rheumatoid 
Arthritis (RA). Methods: The MarketScan Medicaid Multistate Database was used 
to identify adult RA patients indexing on etanercept, adalimumab, or infliximab 
from 2007-2011. The index date was the first index agent claim preceded by 180 days 
and followed by 360 days of continuous enrollment. Patients with conditions other 
than RA were excluded. “Continuing” patients had ≥ 1 claim in the 180 days pre-
index for their index biologic; “new” patients did not. Cost per treated patient was 
calculated in the 360 day post-index period for each index agent as the total index 
drug and administration costs to the payer and the costs of switched-to agents, 
divided by the number of patients who received the index agent. Costs were based 
on the amount of drug used (mg) multiplied by the September 2013 Wholesale 
Acquisition Cost. Treatment patterns were also described. Results: A total of 1,085 
patients met the study criteria: 48% received etanercept (n= 521); 37% received adali-
mumab (n= 405); and 15% received infliximab (n= 159). Patient characteristics were 
similar across treatment groups (mean age 47.4 years, 83% female). The annual cost 
per treated patient was lowest for etanercept ($18,466), followed by adalimumab 
($20,983) and infliximab ($26,516). For all agents, annual costs were lower for new 
patients ($17,996 for etanercept, $18,992 for adalimumab, and $24,756 for infliximab) 
than for continuing patients ($19,004 for etanercept, $24,438 for adalimumab, and 
$28,127 for infliximab). Rates of index drug discontinuation (including switching) 
were 43.8%, 46.2%, and 50.0% for etanercept, adalimumab, and infliximab; switching 
rates were 17.5%, 20.2%, and 31.0%, respectively. ConClusions: Etanercept had 
a lower cost per treated patient compared with adalimumab or infliximab in both 
new and continuing patients among Medicaid enrollees with RA.
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objeCtives: There are no published data on health care costs among rheumatoid 
arthritis (RA) patients treated with subcutaneous abatacept. This study compared 
health care costs between RA patients initiating subcutaneous abatacept or one of 
the two most commonly-used subcutaneous anti-tumor necrosis factor-α agents, 
adalimumab and etanercept. Methods: Retrospective cohort study using a large 
U.S. administrative claims database. Patients included for study had initiated subcu-
taneous abatacept, adalimumab, or etanercept between 1/1/2009-10/1/2012 (index), 
were continuously enrolled for 12 months before (baseline) and ≥ 3 months after 
index, were aged ≥ 18 years at index, and had ≥ 1 baseline medical claim with an 
ICD-9-CM diagnosis code for RA (714.0x). First-line initiators used no biologic pre 
index; second-line initiators used only one biologic pre index. A follow-up period 
extended from index until the first occurrence of switch to another biologic, dis-
enrollment from health insurance, or 12/31/2012. Total health care costs (medical 
+ pharmacy) were measured during baseline and follow-up on a per-patient-per-
month basis. Health care costs were compared using a difference-in-difference (DID) 
analysis [(abatacept $post–abatacept $pre)–(comparator $post–comparator $pre)] 
with Generalized Estimating Equations applied to a two-period (baseline/follow-up) 
panel dataset. A priori-defined sensitivity analyses examined costs when ending 
follow-up at a gap in therapy ≥ 200% of the longest labeled retreatment interval 
for the initiated biologic. Results: The study included 163 abatacept, 7,098 adali-
mumab, and 8,776 etanercept first-line patients; 256 abatacept, 2,055 adalimumab, 
1,303 etanercept second-line patients. In all analyses, abatacept had the numerically 
lowest health care costs, with differences often being statistically significant (first-
line DID: adalimumab= $640, p= 0.0012 // etanercept= $657, p= 0.0010; second-line 
DID: adalimumab= $120, p= 0.0425 // etanercept= $94, p= 0.1304). Sensitivity analyses 
produced consistent results. ConClusions: In this study of RA patients initiating 
first or second-line subcutaneous abatacept, adalimumab, or etanercept, patients 
initiating subcutaneous abatacept had the lowest health care costs according to 
the DID estimator.
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objeCtives: The objectives of this study were to compare health care costs and 
switch rates between rheumatoid arthritis (RA) patients initiating intravenous 
